Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 1

Status

Recruiting 4Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 4Observational 3

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 7Neuromyelitis Optica 2Recurrence 1Optic Neuritis 1Myelitis, Transverse 1Hemoglobinuria, Paroxysmal 1Demyelinating Diseases 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

rozanolixizumab 10zilucoplan 7ravulizumab 7efgartigimod alfa 6eculizumab 5fludarabine 4Cyclophosphamide 4telitacicept 3Tacrolimus 3HBM9161 3inebilizumab 2Mycophenolic Acid 2Diagnostic Self Evaluation 2Amifampridine 2satralizumab 1rhoA GTP-Binding Protein 1remibrutinib 1iscalimab 1iptacopan 1Robotic Surgical Procedures 1Prednisone 1Prednisolone 1Plasmapheresis 1Immunoglobulins, Intravenous 1Data Collection 1Cladribine 1CK-2017357 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Myasthenia Gravis × ravulizumab × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT05644561 2026-04-17

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
12 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Recruiting
40 enrolled

Myasthenia Gravis

NCT03920293 2024-05-28

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
175 enrolled 15 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔